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Background
We have previously shown that the tripeptide glycyl-pro-
lyl-glycine-amide (GPG-amide) inhibits HIV-1 replication
in vitro by affecting proper capsid assembly of HIV-1.
However, GPG-amide failed in a phase II clinical trial on
HIV-infected individuals. In the search for what went
wrong we have now found that the tripeptide in itself does
not exert the antiviral activity but is metabolised in two
steps into the active compound by serum enzymes. The
first step is cleavage of GPG-amide into GP and glycine-
amide (G-amide) by the soluble di-peptidyl peptidase
CD26. In the present study we show that G-amide is fur-
ther metabolised to the actve antiviral substance by an
enzyme present in foetel bovine serum but not in human
serum.
Material and Methods
Numerous methods have been employed including
molecular biology, magnetic resonance (NMR).
Results
The second step is an enzyme mediated oxidation of G-
amide into the active anti-viral compound. By NMR the
molecule was found to be alpha-hydroxy glycine amide
(alphaHGA). The latter is a small molecule with a molec-
ular mass of 90. The conversion of G-amide into
alphaHGA does not take place in human or rodent serum
but in the serum from most species including fetal calf
and pig serum. Hence, GPG-amide does not affect HIV-1
replication if the infected cells are cultured in the presence
of human serum only. We have now synthesized
alphaHGA and been able show that the synthesized sub-
stance inhibits HIV-1 replication in the presence of
human serum only or with heat inactivated fetal calf
serum. In the presence of alphaHGA in the culture
medium progeny HIV-1 particles have abnormal capsid
structures and are non-infectious.
Conclusion
AlphaHGA is a new promising antiretroviral substance.
All preclinical studies on alphaHGA have now been per-
formed and clinical studies on HIV infected individuals
are planned to start this year.
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